Clearmind advances CMND-100 into alcohol use disorder patients after Phase I/II safety milestone

• Clearmind Medicine advanced its FDA-regulated Phase I/II trial of CMND-100 into patient testing for alcohol use disorder.
• Results were already presented from Part A, which met the primary safety endpoint and showed tolerability in healthy participants.
• Part B will test CMND-100 in moderate to severe alcohol use disorder patients, targeting early signs of reduced drinking and craving.
• Part C will dose healthy participants for five days to further characterize the safety and tolerability profile.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clearmind Medicine Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608130736PRIMZONEFULLFEED9809480) on August 13, 2026, and is solely responsible for the information contained therein.